Press Releases

Bethesda, Md., May 7, 2018 – The Parenteral Drug Association (PDA) and the International Society of Pharmaceutical Engineers (ISPE) announced today that they have signed a Memorandum of Understanding (MOU) to exchange information regarding their respective efforts on Quality Metrics and Quality Culture.

Bethesda, Md., April 30, 2018 – The Parenteral Drug Association (PDA) is proud to present its inaugural Pharmacopoeia Conference held at the Renaissance Wien Hotel, May 29-30, Vienna, Austria, which features lectures from representatives of the pharmacopoeias for Europe, the United States, Russia, China, Japan, India, and Ghana. The European Directorate for Quality of Medicines & Healthcare (EDQM) is chairing the conference.

Bethesda, Md., April 23, 2018 – The Parenteral Drug Association (PDA) is pleased to announce that Tina Morris, PhD, has been named Vice President of Scientific and Regulatory Affairs, effective June 4, 2018. Dr. Morris currently serves as Sr. VP of Compendial Sciences at the U.S. Pharmacopeia, with whom she has worked for 15 years.

Bethesda, Md., April 13, 2018 – The Parenteral Drug Association (PDA) announced today that it is expanding its pharmaceutical packaging program with the addition of two trainings in Seoul, Korea and the publication of a book and a survey on pharmaceutical glass.

Bethesda, Md., March 16, 2016 – The Parenteral Drug Association (PDA) is pleased to announce the official launch of its Quality Culture Transformation Program for pharmaceutical manufacturers. Enrollment in the Quality Culture Transformation Program gives companies access to four tools to measure and ultimately improve their commitment to quality.

Bethesda, Md., January 30, 2018 – The Parenteral Drug Association (PDA) today announced its 2018 events calendar, which includes 35 conferences and workshops. These events are developed by all-volunteer subject-matter experts who work with PDA staff to help educate pharmaceutical professionals on important topics related manufacturing science, quality and regulatory affairs.

Bethesda, Md., January 12, 2018 – The Parenteral Drug Association, Inc. (PDA) announced today the speaker line-ups for its parenteral glass/packaging conferences taking place Jan. 23-24 at the Omni Shoreham Hotel in Washington, DC and Feb. 27-28 at the Marriott Rome Park Hotel in Rome.

Bethesda, Md., November 28, 2017 – The Parenteral Drug Association (PDA) today announced the results of its Board of Directors Election for the term beginning January 1, 2018. The 2017 election included candidates for the Board’s Executive Committee and four Director positions.

Bethesda, Md., November 20, 2017 – The Parenteral Drug Association (PDA) gathered experts in pharmaceutical manufacturing, big data and manufacturing intelligence for a “Big Data & Insights from the Shop Floor” ideation session.

Bethesda, Md., October 25, 2017 – The Parenteral Drug Association (PDA) and the International Society of Pharmaceutical Engineers (ISPE) today released a joint statement confirming their combined commitment to fulfilling their respective missions and guiding their members and stakeholders toward using the best science and engineering to continue to provide high-quality, safe, and effective medicines to serve patients. The two not-for-profit membership associations also affirmed their commitment to continuing our collaborations that provide unbiased platforms for dialogue to benefit the global pharmaceutical and biopharmaceutical community.

Bethesda, Md., August 31, 2017 – The Parenteral Drug Association (PDA) published Points to Consider for Aging Facilities as part of an ongoing focus on manufacturing improvements. In some cases, noncompliant, aging facilities are a reason forcing companies to cease manufacturing, which may exacerbate drug shortages.

Bethesda, Md., July 28, 2017 – The Parenteral Drug Association (PDA) today announces the results of its pharma/biopharma survey regarding the impact of national-level post-approval change regulations on company’s ability to innovate.

Bethesda, Md., June 12, 2017 – The Parenteral Drug Association (PDA) today announced the successful completion of its Annex 1 Revision Workshop, which afforded industry a final preview before the revised guidance for aseptic processing GMPs is issued as early as the end of the month.

Bethesda, Md., May 25, 2017 – The Parenteral Drug Association (PDA) is proud to announce a significant initiative to bring together executives, including CEOs and executive vice presidents, from biologic and pharmaceutical manufacturers with glass container and elastomeric closure suppliers to prepare industry for the complex products and manufacturing processes of the future.

Bethesda, Md., May 15, 2017 – The Parenteral Drug Association (PDA) today announced the publication of Technical Report No. 54-5: Quality Risk Management for the Design, Qualification, and Operation of Manufacturing Systems,which provides a practical guide on how to manage quality risks throughout the manu­facturing system lifecycle. Technical Report 54-5 includes two case studies illustrative of the concepts developed in the main body of the document. In June, PDA is sponsoring the 2017 Quality Risk Management for Manufacturing Systems Workshop,which will cover the concepts elucidated in Technical 54-5, at the Hyatt Centric Chicago Magnificent Mile, Chicago, Ill., June 19-20.

Bethesda, Md., May 8, 2017 – The Parenteral Drug Association, Inc. (PDA) is pleased to announce that President & CEO Richard Johnson, volunteer Chair Martin Van Trieste, and past chairs Maik Jornitz and James Agalloco have been recognized by The Medicine Maker among the "top 100 individuals involved in bettering the pharma industry and bringing life-changing medicines to market."

Bethesda, Md., May 3, 2017 – The Parenteral Drug Association (PDA) today released the names of confirmed health authority speakers at its 2017 Revision of Annex 1 Workshop, at the Hilton Berlin, June 12, 2017, which precedes the 2nd PDA Europe Annual Meeting: Global Healthcare of the Present & Future, June 13-14.

Anaheim, Ca. April 3, 2017 – The Parenteral Drug Association (PDA) today announced that it has been approved by the Executive Standards Council (ExSC) of the American National Standards Institute (ANSI) as an Accredited Standard Developer (ASD). The announcement was made during the opening session of PDA’s Annual Meeting at the Anaheim Marriott.

Bethesda, Md., March 2, 2017 – The Parenteral Drug Association (PDA) today announced the availability of two “PDA Papers” authored by the Post-Approval Changes for Innovation in Availability of Medicines (PAC iAM) Task Force in the “Accepted Articles” section of the PDA Journal of Pharmaceutical Science and Technology (PDA Journal).

Bethesda, Md., February 27, 2017 – The Parenteral Drug Association (PDA) today announced the completion of a six-month enlargement of its Training and Research Institute (TRI) in Bethesda. The expansion permits PDA Education to increase its capacity for hands-on aseptic processing and lecture-based training at TRI.